Retigabine (INN) or ezogabine (USAN) is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. [2] . The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline.

2025年1月7日 · Retigabina (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy.

Retigabine is 50–60% bioavailable, metabolized by N-glucuronidation and N-acetylation, 80% protein bound, and has few drug–drug interactions. Recent data suggest that retigabine may have a role as adjunctive treatment for refractory partial-onset seizures.

Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. The drug has been extensively studied in phase I and II studies, with very promising results.

Introduction: Retigabine (RTG) is now approved in Europe and the US for the adjunctive treatment of partial-onset seizures in adults with epilepsy. To support submissions to EU reimbursement authorities, we explored its efficacy and tolerability relative to selected antiepileptic drugs (AEDs).

Retigabine is a commercial antiepileptic drug that increases currents through potassium channels, potentially reversing the effects of specific mutations associated with BFNE. You might find these chapters and articles relevant to this topic.

Randomized, placebo-controlled multicenter studies have shown that retigabine produced a considerable improvement as an add-on drug in patients with partial drug-resistant epilepsy. The most prominent adverse effects due to retigabine combined with the existing antiepileptic treatment were dizziness, somnolence and fatigue.

2011年9月30日 · Ezogabine is approved by the FDA for the adjunctive treatment of partial-onset seizures in patients aged 18 years and older 4. It is authorized by the European Commission for the adjunctive...

2012年1月5日 · In this article, we consider the pharmacologic characteristics of RTG/EZG at the receptor, cellular, and network levels as a means of understanding the novel and efficacious MoA of this new AED as defined in both preclinical and clinical research.

Seleccione la ficha técnica de un medicamento o producto sanitario compuesto por el principio activo RETIGABINA para acceder a toda su información: instrucciones o prospecto, número de registro del medicamento, nombre comercial del medicamento, dosis del medicamento, forma farmacéutica, tipo de envase, contenido, laboratorio comercializador ...